

# Discovery

## Q1 investment update

April 2025

---

Investment manager Douglas Brodie and client relationship manager Beth Harris give an update on the Global Discovery and Worldwide Discovery strategies covering Q1 2025.

---

**Your capital is at risk. Past performance is not a guide to future returns.**

**Beth Harris (BH):** Hello and welcome to this quarter's update for the Discovery Strategy. As a reminder, Discovery looks to find the next generation of excellent growth companies. We find them when they're young and we hold them for the long term as they scale. My name is Beth Harris and I'm a specialist in the clients team and I'm joined by Douglas Brodie who's the head of the strategy. Hi Douglas.

**Douglas Brodie (DB):** Hello.

**BH:** So it's fair to say it's been a very volatile start to 2025. We're just interested to hear how you're thinking about that ever-changing environment.

**DB:** Sure. So, as I reflect, I'd say 2024 was a period of consolidation. You had moderation in inflation. You had excitement towards the end of the year with the new regime coming in in the US. And then as you went into January post the inauguration, I'd say attitudes hardened, frankly, attitudes both within stock markets and politically. That whole 'make America great' mantra clearly had implications that extended well beyond the borders of the US.

You had the emergence of tariffs as a pretty blunt diplomacy tool, and you had a real storm blowing through Washington in terms of various government departments, a sort of real resetting of the agenda. And this made for a melting pot of uncertainty. And stock markets, they struggle at times like that.

So what does this all mean for interest rates, inflation, economic growth, technology, supremacy? I think these are all very valid questions that people are wrestling with. And I'm not trying to downplay them because they are incredibly hard to answer at a period of flux.

But, you know, there's a real resetting of concepts that have been around for decades. US hegemony, US exceptionalism, a real resetting of some of the alliances that have been in place for a long period of time.

So, trying to understand what that means for the long-term investing landscape. At the very least, I think it means more reshoring and resiliency built into business models.

**BH:** So what you've described is quite a significant shift from where we were at the end of 2024. Has that translated to changes in the portfolio?

**DB:** Yeah, I would say some of these things we've been in tune with before. Now, fair enough, their magnitude has probably surprised us. Businesses like MP Materials. So they are a rare earth miner based in California, mining rare earths that are particularly useful for making very high-performing magnets.

So anytime you want to convert electrical energy into kinetic energy, you need these magnets. And historically, China has been the dominant provider of that. But we're excited about MP materials because we think they have a really interesting claim to become one of, if not the only, vertically integrated supplier in the Western world of these magnets.

Another example would be Xometry. So Xometry is a really interesting marketplace that connects the users and buyers of industrial parts with a very fragmented base of parts suppliers. So milling machines, machine shops, 3D printing businesses, etc. And they deliver real value for both sides in that equation.

And what we're seeing is that companies now really value an adaptability, a dynamic, almost intelligent aspect to how they can source products, how they can scale that up very, very effectively. And that whole offering of Xometry is moving away from being sort of prototypes and low volume parts, into providing much bigger orders for bigger businesses. So very much in tune with that sort of self-resiliency that companies want.

I'd also say it's been an environment where it has been more valuation-sensitive. We've been in tune with that with reductions that we've made to businesses like Doximity and Axon that have performed very well. But it's also an environment where companies that deliver real value, real efficiency and real revenue boosting potential for their clients, that still very much resonates.

So we've purchased an interesting business called Amplitude that really helps companies build better websites, drive better conversions, consolidate a base of tools that historically they'd be doing that with to do that more effectively and drive better revenue growth for them.

**BH:** Excellent, thanks. Sticking with the portfolio, I guess, a company, Aerovironment, has had a particularly difficult quarter. Can you explain what's gone on there, please?

**DB:** Yeah, there's been a couple of noisy effects around AeroVironment. So, they manufacture drones largely for a military customer base. And Ukraine over the past few years, for reasons that we all know, has become a sort of real test bed, a real use case for those devices, and AeroVironment have carried material exposure to that.

As that sort of conflict begins to move into a different phase, people are worried about, you know, what does that mean for the future growth on a short-term view for air environment. As a business, they also had a disruption from some of the LA fires, their main headquarters manufacturing facilities are in that area, and that provided some disruption.

So we think both of those incidents are near-term, they're manageable. And what we're seeing, frankly, at the business level is a real explosion in their order book, huge interest from customers all around the world, but particularly, I would say, on the eastern flanks of Europe. South China Sea, and the US very much keen to have more of these in their arsenal.

**BH:** Okay, so no change to the initial investment case there. Another company, Alnylam, seems to be going from strength to strength. So is there any significant news there?

**DB:** Yeah, a couple of very interesting news points. One I know we've covered in this format before. They had FDA approval very recently for one of their drugs for a rare form of heart failure. But perhaps less well known, they've also had approval for a drug that they've got partnered with Sanofi. And this is a drug for haemophilia.

So roughly about a million patients in the world who inherit genetic disorders related to haemophilia, various forms of that disease. Alnylam's drug works in all forms of that disease, and crucially, it also works in patients that have historically developed an immune response to the conventional therapies. So we think that's a really interesting drug with a big potential.

**BH:** Great. And I guess just to kind of close things out with your concluding thoughts, how are you thinking about things going forward and the outlook from here?

**DB:** Yeah, we're very enthused by the portfolio. When we look down at the portfolio, we have a collection of businesses that have earnings growth potential over the next three years. There's about double what we think the broader market can offer. We get deeply excited about where we think these businesses will get to on that three-, five- and ten-year view. And as much as the current environment is noisy and unhelpful, we take that enthusiasm from the businesses that we invest in.

**BH:** Great. Thanks so much, Doug. And that brings us to the end of this quarter's update. Thank you.

## Discovery (representing Global Discovery and Worldwide Discovery strategies)

### Annual past performance to 31 March each year (net%)

	2021	2022	2023	2024	2025
Worldwide Discovery Composite*	99.5	-31.0	-26.8	-9.4	-5.2
MSCI ACWI Small Cap Index	82.7	0.0	-9.1	17.0	0.0

### Annualised returns to 31 March 2025 (net%)

	1 year	5 years	10 years	Since inception
Worldwide Discovery Composite*	-5.2	-2.9	N/A	2.4
MSCI ACWI Small Cap Index	0.0	14.2	N/A	6.6

\*Inception date: 30 June 2017.

Source: Revolution, MSCI. US dollars. Returns have been calculated by reducing the gross return by the highest annual management fee for the composite. 1 year figures are not annualised.

Past performance is not a guide to future returns.

Legal notice: MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indexes or any securities or financial products. This report is not approved, endorsed, reviewed or produced by MSCI. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

### Risk factors

This communication was produced and approved in April 2025 and has not been updated subsequently. It represents views held at the time and may not reflect current thinking.

The views expressed should not be considered as advice or a recommendation to buy, sell or hold a particular investment. They reflect opinion and should not be taken as statements of fact nor should any reliance be placed on them when making investment decisions.

This communication contains information on investments which does not constitute independent research. Accordingly, it is not subject to the protections afforded to independent research, but is classified as advertising under Art 68 of the Financial Services Act ('FinSA') and Baillie Gifford and its staff may have dealt in the investments concerned.

All information is sourced from Baillie Gifford & Co and is current unless otherwise stated.

The images used in this communication are for illustrative purposes only.

## Important information

Baillie Gifford & Co and Baillie Gifford & Co Limited are authorised and regulated by the Financial Conduct Authority (FCA). Baillie Gifford & Co Limited is an Authorised Corporate Director of OEICs.

Baillie Gifford Overseas Limited provides investment management and advisory services to non-UK Professional/Institutional clients only. Baillie Gifford Overseas Limited is wholly owned by Baillie Gifford & Co. Baillie Gifford & Co and Baillie Gifford Overseas Limited are authorised and regulated by the FCA in the UK.

Persons resident or domiciled outside the UK should consult with their professional advisers as to whether they require any governmental or other consents in order to enable them to invest, and with their tax advisers for advice relevant to their own particular circumstances.

## Financial intermediaries

This communication is suitable for use of financial intermediaries. Financial intermediaries are solely responsible for any further distribution and Baillie Gifford takes no responsibility for the reliance on this document by any other person who did not receive this document directly from Baillie Gifford.

## Europe

Baillie Gifford Investment Management (Europe) Ltd (BGE) is authorised by the Central Bank of Ireland as an AIFM under the AIFM Regulations and as a UCITS management company under the UCITS Regulation. BGE also has regulatory permissions to perform Individual Portfolio Management activities. BGE provides investment management and advisory services to European (excluding UK) segregated clients. BGE has been appointed as UCITS management company to the following UCITS umbrella company; Baillie Gifford Worldwide Funds plc. BGE is a wholly owned subsidiary of Baillie Gifford Overseas Limited, which is wholly owned by Baillie Gifford & Co. Baillie Gifford Overseas Limited and Baillie Gifford & Co are authorised and regulated in the UK by the Financial Conduct Authority.

## Hong Kong

Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 is wholly owned by Baillie Gifford Overseas Limited and holds a Type 1 license from the Securities & Futures Commission of Hong Kong to market and distribute Baillie Gifford's range of collective investment schemes to professional investors in Hong Kong. Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 can be contacted at Suites 2713-2715, Two International Finance Centre, 8 Finance Street, Central, Hong Kong. Telephone +852 3756 5700.

## South Korea

Baillie Gifford Overseas Limited is licensed with the Financial Services Commission in South Korea as a cross border Discretionary Investment Manager and Non-discretionary Investment Adviser.

## Japan

Mitsubishi UFJ Baillie Gifford Asset Management Limited ('MUBGAM') is a joint venture company between Mitsubishi UFJ Trust & Banking Corporation and Baillie Gifford Overseas Limited.

MUBGAM is authorised and regulated by the Financial Conduct Authority.

## Australia

Baillie Gifford Overseas Limited (ARBN 118 567 178) is registered as a foreign company under the Corporations Act 2001 (Cth) and holds Foreign Australian Financial Services Licence No 528911. This material is provided to you on the basis that you are a "wholesale client" within the meaning of section 761G of the Corporations Act 2001 (Cth) ("Corporations Act"). Please advise Baillie Gifford Overseas Limited immediately if you are not a wholesale client. In no circumstances may this material be made available to a "retail client" within the meaning of section 761G of the Corporations Act.

This material contains general information only. It does not take into account any person's objectives, financial situation or needs.

## South Africa

Baillie Gifford Overseas Limited is registered as a Foreign Financial Services Provider with the Financial Sector Conduct Authority in South Africa.

## North America

Baillie Gifford International LLC is wholly owned by Baillie Gifford Overseas Limited; it was formed in Delaware in 2005 and is registered with the SEC. It is the legal entity through which Baillie Gifford Overseas Limited provides client service and marketing functions in North America. Baillie Gifford Overseas Limited is registered with the SEC in the United States of America.

The Manager is not resident in Canada, its head office and principal place of business is in Edinburgh, Scotland. Baillie Gifford Overseas Limited is regulated in Canada as a portfolio manager and exempt market dealer with the Ontario Securities Commission ('OSC'). Its portfolio manager licence is currently passported into Alberta, Quebec, Saskatchewan, Manitoba and Newfoundland & Labrador whereas the exempt market dealer licence is passported across all Canadian provinces and territories. Baillie Gifford International LLC is regulated by the OSC as an exempt market and its licence is passported across all Canadian provinces and territories. Baillie Gifford Investment Management (Europe) Limited ('BGE') relies on the International Investment Fund Manager Exemption in the provinces of Ontario and Quebec.

## Israel

Baillie Gifford Overseas Limited is not licensed under Israel's Regulation of Investment Advising, Investment Marketing and Portfolio Management Law, 5755-1995 (the Advice Law) and does not carry insurance pursuant to the Advice Law. This material is only intended for those categories of Israeli residents who are qualified clients listed on the First Addendum to the Advice Law.

## **Singapore**

Baillie Gifford Asia (Singapore) Private Limited is wholly owned by Baillie Gifford Overseas Limited and is regulated by the Monetary Authority of Singapore as a holder of a capital markets services licence to conduct fund management activities for institutional investors and accredited investors in Singapore. Baillie Gifford Overseas Limited, as a foreign related corporation of Baillie Gifford Asia(Singapore) Private Limited, has entered into a cross-border business arrangement with Baillie Gifford Asia (Singapore) Private Limited, and shall be relying upon the exemption under regulation 4 of the Securities and Futures (Exemption for Cross-Border Arrangements) (Foreign Related Corporations) Regulations 2021 which enables both Baillie Gifford Overseas Limited and Baillie Gifford Asia (Singapore) Private Limited to market the full range of segregated mandate services to institutional investors and accredited investors in Singapore.